Pershing Edward bought PVCT
February 9, 2026 · Form 4 insider transaction
Pershing Edward bought 34,940 shares of Provectus Biopharmaceuticals, Inc. at $2.86 per share, a transaction worth $100.0K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
The Reporting Person acquired 34,940 shares of Series D-1 Preferred Stock in a private transaction.; Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").; The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.